Growth Metrics

Plus Therapeutics (PSTV) Invested Capital (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Invested Capital for 16 consecutive years, with $4.7 million as the latest value for Q4 2025.

  • Quarterly Invested Capital rose 183.9% to $4.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.7 million through Dec 2025, up 183.9% year-over-year, with the annual reading at $4.7 million for FY2025, 183.9% up from the prior year.
  • Invested Capital for Q4 2025 was $4.7 million at Plus Therapeutics, down from $5.1 million in the prior quarter.
  • The five-year high for Invested Capital was $21.5 million in Q3 2021, with the low at -$23.6 million in Q1 2025.
  • Average Invested Capital over 5 years is $5.5 million, with a median of $7.0 million recorded in 2023.
  • Peak annual rise in Invested Capital hit 368.54% in 2025, while the deepest fall reached 1795.83% in 2025.
  • Over 5 years, Invested Capital stood at $21.5 million in 2021, then crashed by 62.56% to $8.1 million in 2022, then crashed by 67.37% to $2.6 million in 2023, then tumbled by 315.26% to -$5.7 million in 2024, then surged by 183.9% to $4.7 million in 2025.
  • According to Business Quant data, Invested Capital over the past three periods came in at $4.7 million, $5.1 million, and $3.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.